Kathleen Ford sold $112k of KURA
Chief Operating Officer at Kura Oncology, Inc.. 10,574 shares at an average of $10.59, traded Sep 28, 2026, filed Sep 29, 2026.
Score components
- +20RoleCOO
- +10Trade size$112k at market
- 0Share of holdings soldSold 6.9% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-407938, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | SOpen-market sale Common Stock10b5-1 | -6,906 | $10.50 | $72k | 146,654 | 14 d ago |
| Sep 29, 2026 | SOpen-market sale Common Stock10b5-1 | -3,668 | $10.75 | $39k | 142,986 | 14 d ago |
Related signals
Other insiders at Kura Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | Kura Oncology, Inc. | Teresa Brophy Bair Chief Legal Officer | $89k 8,442 shares | -4% | |
| 37Weak | Kura Oncology, Inc. | Thomas James Doyle SVP, Finance & Accounting | $48k 4,607 shares | -3% | |
| 30Weak | Kura Oncology, Inc. | Brian T. Powl Chief Commercial Officer | $345k 32,450 shares | -19% | |
| 32Weak | Kura Oncology, Inc. | Mollie Leoni Chief Medical Officer | $440k 41,250 shares | -23% | |
| 37Weak | Kura Oncology, Inc. | Francis Burrows Chief Scientific Officer | $225k 20,726 shares | -33% | |
| 28Weak | Kura Oncology, Inc. | Mollie Leoni Chief Medical Officer | $834k 84,929 shares | -32% | |
| 20Weak | Kura Oncology, Inc. | Brian T. Powl Chief Commercial Officer | $110k 10,000 shares | -5% | |
| 10Weak | Kura Oncology, Inc. | Teresa Brophy Bair Chief Legal Officer | $21k 2,256 shares | -1% | |
| 15Weak | Kura Oncology, Inc. | Kathleen Ford Chief Operating Officer | $20k 2,257 shares | -1% | |
| 10Weak | Kura Oncology, Inc. | Brian T. Powl Chief Commercial Officer | $3,122 339 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.